论文部分内容阅读
目的对三周多西他赛联合顺铂、5-氟尿嘧啶治疗晚期胃癌的有效性和安全性进行荟萃分析,以期更有效地指导临床用药。方法采用Cochrane协作网提供的专用软件RevMan5.0对各纳入研究进行Meta分析。结果与结论三周多西他赛联合顺铂、5-氟尿嘧啶(DCF方案)对晚期胃癌的近期疗效总体优于其他临床常用化疗方案(RR1.30,95%CI1.11-1.51),然而,Ⅲ-Ⅳ级白细胞减少的发生情况总体显著高于其他对照组(RR1.54,95%CI1.15-2.07),Ⅲ-Ⅳ级恶心呕吐的发生情况总体则与其他对照组无差别(RR1.00,95%CI0.80-1.26)。
Objective To evaluate the efficacy and safety of three weeks docetaxel plus cisplatin and 5-fluorouracil in the treatment of advanced gastric cancer in order to guide the clinical medication more effectively. Methods Using the software RevMan5.0 provided by the Cochrane Collaboration, we conducted a meta-analysis of each inclusion study. RESULTS AND CONCLUSION: The short-term curative effect of docetaxel combined with cisplatin and 5-fluorouracil (DCF) on advanced gastric cancer was better than other commonly used regimens (RR1.30, 95% CI1.11-1.51) The incidence of grade Ⅲ-Ⅳ leukopenia was significantly higher than that of other control groups (RR 1.54, 95% CI 1.15-2.07). The incidence of grade Ⅲ-Ⅳ nausea and vomiting was not significantly different from that of other control groups (RR1. 00, 95% CI 0.80-1.26).